Linfomaymieloma.com

NEW PROPOSED DOSE MODIFICATION GUIDELINE FOR BORTEZOMIB

Severity of PN Signs and Symptoms
Grade 1 (parasthesias, weakness, and/or loss of reflexes) without pain or loss of function
Modification of Bortezomib Dose and Regimen
Reduce current bortezomib dose by one level (1.3 1.0 ->

FDA Approves Lenalidomide (Revlimid) for Mantle Cell Lymphoma

On June 5, 2013, the U. S.

Brentuximab vedotin is used to treat adults with Hodgkin lymphoma (HL, a type of cancer that originates from blood cells in the lymphatic system, a part of the immune system) when the tumour cells are CD30-positive (when they have a protein called CD30 on their surface).

It is used when the cancer has come back or has not responded to an autolog

PTCL-NOS is the largest group of  T-cell lymphomas, accounting for around half of the cases seen and 3-7% of all lymphomas.

Patients with PTCL-NOS have a median age of about 60 years, a striking male predominance, and usually present with widespread disease

While the International Prognostic Index has a significant association with treatment

Also known as angiofollicular or giant lymph node hyperplasia, the clinical manifestations of Castleman disease (CD) are heterogeneous, ranging from asymptomatic discrete lymphadenopathy to recurrent episodes of diffuse lymphadenopathy with severe systemic symptoms.

The pathogenesis is unknown, but the bulk of evidence points toward faulty immun

It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results in myeloma. The goal of the International Myeloma Workshop Consensus Panel 1 was to develop a set of guidelines for the uniform reporting of clinical trial results in myeloma.

Kumar et al (Mayo Clinic) examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time.

The European Medicines Agency (EMEA) has recommended the approval of Thalidomide Pharmion (thalidomide) for the treatment of multiple myeloma.
Meeting on 21-24 January 2008, the Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Thalidomide Pharmion in combination with melphalan and prednisone outweigh

Multiple myeloma is a B-cell malignancy with terminally differentiated plasma cell phenotype.
Multiple myeloma (MM) accounts for 1% of all malignancies.
The characteristic findings in MM are lytic bone disease, renal insufficiency, anemia, hypercalcemia, and immunodeficiency.